stackBETA

Daily

  • Log

Verify

  • Cabinet · stacks
  • Vials · inventory

Build

  • Reconstitution

Plan

  • Can I get it?
  • Compare
  • Synergy check

Learn

  • Encyclopedia
  • Common stacks
  • Pulse
  • Methodology

Info

  • Partners & programs

Stack · v0.1 beta

stackBETAv0.1
LogEncyclopediaPulse
MethodologyPartners & programs
← Back to your stack
Monograph
FDA CAT. 1S-013
Longevity

Nicotinamide Riboside (NR / Niagen)

NAD+ precursor — converts to NMN then NAD+ via the salvage pathway. Sister molecule to NMN with similar end-state biology. Chromadex commercialized as Niagen (FDA-GRAS 2016).

EmergingLongevity
Typical dose250-1000 mg
Frequencydaily, oral
Half-life7h
Citations indexed89
100%50%0%07h14h21h1.2d1.5dt½ 7hPK · plasma

How it clearsHalf cleared in ~7h. Most (~96%) gone by ~1d.

DeliveryOral
Half-life~7h
EvidenceEmerging
Citations89
Similar compounds
Stack Pro · compare side-by-side

Compare these compounds

Mechanism, evidence, legal path, cost — all side-by-side.

→
Synergy checkCompare
Mechanism

More published human RCTs than NMN as of 2026 (the NR commercialization predates the NMN wave by ~5 years). Trammell 2016 first-in-human study + multiple follow-ups document dose-dependent NAD+ pool rise. Clinical-outcome benefits remain modest: small signals in blood-pressure (Martens 2018), exercise-recovery (Dolopikou 2020), Parkinson's biomarkers (Brakedal 2022). No large mortality or healthspan RCT. NMN is the more-hyped molecule in 2024-26 but the NR evidence base is actually deeper.

Specifics
Cellular aging concernsMitochondrial energy declineLow energy / fatigue
Caveats

Hype outpaces clinical-outcome evidence. Biomarker shifts (raised NAD+ pool) are real and replicate; mortality + healthspan endpoints have not been studied at scale. ChromaDex vs Elysium NR-vs-Basis patent dispute is a brand-decision noise factor, not a biology factor. Long-term NAD+ pool elevation has theoretical concerns around methylation balance + theoretical cancer-cell metabolism support.

Evidence levelEmerging
Regulatory statusFDA-GRAS supplement (2016) · ChromaDex commercial (Niagen + ingredient supply for ~75 other brands)
DNA / pharmacogenomicsLow — NAMPT polymorphisms theoretically modulate; PG not actionable.
Your data · empty

Upload your data to see how it relates to NR.

Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.

Upload in /history→
Claims & evidence

Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.

  • AStrong evidence

    Raises systemic NAD+ pool dose-dependently in humans.

    1 supporting referencesVerified today
  • CLimited evidence

    Extends healthspan or reduces age-related disease incidence in humans.

    1 supporting referencesVerified today
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • PubMedEN
    RCTAcademic-funded
    Trammell SAJ et al, Nat Commun 2016 — NR first-in-human PK
  • PubMedEN
    RCTAcademic-funded
    Martens CR et al, Nat Commun 2018 — NR blood pressure RCT
FDA CAT. 1S-013

FDA-GRAS supplement (2016) · ChromaDex commercial (Niagen + ingredient supply for ~75 other brands)

Can I get it? →

No field reports yet

Field reports are added as users share their real-world protocols.

NR250-1000 mg · daily, oral

Next visit & citations

Handoff & sources

Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.

Open Dr PassportMethodologyResearch tableClinician primer
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesPartners & programsWho Stack is forFor creatorsFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.
TodayLibrary
ToolsMe